All Posts

Non-small cell lung cancer emerging therapies
Non-small cell lung cancer emerging therapies

The Non-small cell lung cancer therapeutics market is anticipated to improve owing to better diagnostics methodologies and treatment options across the world. This would expand the NSCLC market size enabling the drug manufacturers to penetrate more into the market. Companies across the globe are diligently working ...

Find More

Pharma News
AstraZeneca tops the first Pharma Invention Index; Amgen to buy 20.5% stake in a Chinese pharmaceutical, BeiGene; Ascentage, Henlius collaborates to develop a Combination therapy

Amgen has announced to purchase 20.5% of the stake in Chinese-American drug company BeiGene. As per the deal signed, Amgen will develop and commercialize around two dozen of its on-market as well as experimental drug compounds for the treatment of cancer in China. The shares purchased are worth USD 2.7 bill...

Find More

Sanfilippo syndrome market
The growing size of Sanfilippo syndrome Market: Drivers and Barriers

Sanfilippo syndrome, also known as mucopolysaccharidosis type III (MPS III), is a rare genetic disorder that affects the Central Nervous system. It is a result of a mutation in genes and can be of four types (A, B, C, and D). In all the four cases, the body fails to clear up the toxic sugars such as mucopolysacchar...

Find More

Non-Small Cell Lung Cancer Market
Non-Small Cell Lung Cancer Market: Treatments and Market Forecast

An estimated number of 18.1 million new cancer cases were registered last year, according to A Cancer Journal for Clinicians 2018;0:1‐31. Moreover, it is a leading cause of global deaths. The deaths due to cancer remain recognized as the only barrier in the increasing life expectancy in the world. The incidence, as...

Find More

Pharma News
AZ sells EU rights for Schizophrenia to Cheplapharm; Astellas, Pandion unite to extract the potential of immunomodulation; Pear therapeutics on a journey to develop digital GI treatments with Ironwood

AstraZeneca has announced the licensing-out of two of its drugs Seroquel and Seroquel XR in Europe and Russia to Cheplapharm Arzneimittel GmbH. According to the deal signed between the companies, AZ will receive an upfront payment of USD 178 Million, in addition to other payments upon achieving sales milestones...

Find More

Geographic atrophy market
Geographic Atrophy Treatment Market: Novel Therapies to Enter the Market

Geographic atrophy (GA) is a severe, progressive, irreversible vision loss in old age people. The loss in the vision is due to the damage in a small portion of the retina at the back of the eye, known as the macula. Since the loss of vision is due to age, it is also referred to as Age-related macular degeneration. ...

Find More

World Psoriasis Day
World Psoriasis Day

World Psoriasis Day, observed on 29th October every year to raise awareness globally and spread information about psoriasis and psoriatic arthritis. Psoriasis generally occurs from an overactive immune system resulting in skin rashes. Around 0.5-2.8% of the Indian population is affected by this disease. Psoriasis c...

Find More

Pharma News
AZ announces positive results for durvalumab and tremelimumab; FDA nods to extend LILETTA’s use to prevent pregnancy; Gilead, Glympse Bio teams up to advance NASH clinical development

AstraZeneca recently has announced the results of the clinical trials POSEIDON which included the study of a combination of drugs Imfinzi (durvalumab) and tremelimumab with chemotherapy in lung cancer. Imfinzi is a human monoclonal antibody which blocks the interaction of PD-L1 with PD-1 by binding itself with ...

Find More

Refractory Metastatic Melanoma Market
Refractory Metastatic Melanoma Market

The cases of Melanoma have been on a hike for the past thirty years making it the fifth most common cancer among people. By the end of the year 2019, an estimated number of 57,220 men and 39,260 women in the United States would have been diagnosed with invasive melanoma, as per Cancer.net. Melanoma is the rarest...

Find More

onychomycosis therapies
Onychomycosis therapeutics market: Impact of new topical anti-fungal drugs

A very common, although not a life-threatening fungal infection of the nail, Onychomycosis is regarded as a serious health problem because of increasing global prevalence. According to a study by P. Dyanne et al, Onychomycosis occurs in 10% of the general population but is more common in older adults; the preva...

Find More